Home › Funds › Candriam S.C.A. › ALNY
Candriam S.C.A. position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Candriam S.C.A. reported holding 314,512 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$94.6M, representing 0.43% of its reported portfolio and ranking #46 among its reported holdings. Candriam S.C.A. has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Candriam S.C.A.'s ALNY position evolved
Candriam S.C.A. first disclosed a stake in ALNY in Q3 2023 at 328,894 shares (US$58.2M). The position peaked in Q3 2025 at 212,416 shares, worth US$96.9M. Across 12 filings, Candriam S.C.A. increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 314,512 shares valued at US$94.6M — an increase of 90,182 shares quarter over quarter.. Notable position changes include a 100% trim in Q4 2023 (shares fell 22% over the following quarter), a 751% increase in Q2 2024 (shares rose 13% over the following quarter), a 106108% increase in Q3 2025 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 328.89K | $58.25M | New |
| Q4 2023 | 700 | $693.49K | Reduce |
| Q1 2024 | 800 | $754.51K | Add |
| Q2 2024 | 6.81K | $6.56M | Add |
| Q3 2024 | 520 | $608.47K | Reduce |
| Q4 2024 | 520 | $557.35K | Hold |
| Q1 2025 | 200 | $231.02K | Reduce |
| Q2 2025 | 200 | $258.50K | Hold |
| Q3 2025 | 212.42K | $96.86M | Add |
| Q4 2025 | 224.33K | $89.21M | Add |
| Q1 2026 | 224.33K | $74.22M | Hold |
| Q2 2026 | 314.51K | $94.59M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 2.44M sh · $734.48M · Q2 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- AMERICAN CENTURY COMPANIES INC 1.85M sh · $558.10M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
- Qube Research & Technologies Ltd 798.72K sh · $240.44M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 729.63K sh · $219.64M · Q2 2026
- LOOMIS SAYLES & CO L P 580.19K sh · $174.65M · Q2 2026
More on Candriam S.C.A.
FAQ
How long has Candriam S.C.A. held ALNY?
Candriam S.C.A. has disclosed ALNY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Candriam S.C.A.'s current position in ALNY?
As of Q2 2026, Candriam S.C.A. holds 314.51K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $94.59M, representing 0.43% of its reported portfolio and ranking #46.
Has Candriam S.C.A. been buying or selling ALNY?
In the latest 13F filing (Q2 2026), Candriam S.C.A. increased its position in ALNY. The position peaked in Q3 2025 at 212.42K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.